Marisol Veny

Marisol Veny

Auto-generated profile, based on publicly available information

Marisol Veny

Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Inflammatory Bowel Disease Unit, Department of Gastroenterology, Hospital Clínic de Barcelona

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Open access
BVBram Verstockt
Bram Verstockt
SVSare Verstockt
Sare Verstockt
MVMarisol Veny
Marisol Veny
JDJonas Dehairs
Jonas Dehairs
KAKaline Arnauts
Kaline Arnauts
MFMarc Ferrante
Marc Ferrante
We aimed to identify biomarkers that might be used to predict responses of patients with inflammatory bowel diseases (IBD) to vedolizumab therapy. We obtained biopsies from inflamed colon of patients with IBD who began treatment with vedolizumab (n = 31) or tumor necrosis factor (TNF) antagonists (n = 20) and performed RNA-sequencing analyses. We compared gene expression patterns between patients who did and did not enter endoscopic remission (absence of ulcerations at month 6 for patients with Crohn's disease or Mayo endoscopic subscore ≤1 at week 14 for patients with ulcerative colitis) and performed pathway analysis and cell deconvolution for training (n = 20) and validation (n = 11) datasets. Colon biopsies were also analyzed by immunohistochemistry. We validated a baseline gene expression pattern associated with endoscopic remission after vedolizumab therapy using 3 independent datasets (n = 66). We identified significant differences in expression levels of 44 genes between patients who entered remission after vedolizumab and those who did not; we found significant increases in leukocyte migration in colon tissues from patients who did not enter remission (P < .006). Deconvolution methods identified a significant enrichment of monocytes (P = .005), M1-macrophages (P = .05), and CD4+ T cells (P = .008) in colon tissues from patients who did not enter remission, whereas colon tissues from patients in remission had higher numbers of naïve B cells before treatment (P = .05). Baseline expression levels of PIWIL1, MAATS1, RGS13, and DCHS2 identified patients who did vs did not enter remission with 80% accuracy in the training set and 100% accuracy in validation dataset 1. We validated these findings in the 3 independent datasets by microarray, RNA sequencing and quantitative PCR analysis (P = .003). Expression levels of these 4 genes did not associate with response to anti-TNF agents. We confirmed the presence of proteins encoded by mRNAs using immunohistochemistry. We identified 4 genes whose baseline expression levels in colon tissues of patients with IBD associate with endoscopic remission after vedolizumab, but not anti-TNF, treatment. We validated this signature in 4 independent datasets and also at the protein level. Studies of these genes might provide insights into the mechanisms of action of vedolizumab.

23 December 2023 in Genes & Immunity
Verified
Journal Article
Closed access
PDF file
AGAlba Garrido-Trigo
Alba Garrido-Trigo
MVMarisol Veny
Marisol Veny
ASAZUCENA SALAS
AZUCENA SALAS

9 October 2026 in Research Square
Verified
Preprint
Open access
PDF file
ASAZUCENA SALAS
AZUCENA SALAS
MBMarc Buendia
Marc Buendia
ÁSÁngela Sanzo-Machuca
Ángela Sanzo-Machuca
SSSofia Sabate
Sofia Sabate
MVMarisol Veny
Marisol Veny
ERElena Ricart
Elena Ricart
Granulomas are a defining feature of Crohn’s disease associated with a more severe disease course, yet their developmental origins and cellular organization remain poorly understood. Here, we integrate single-cell and spatial transcriptomics of human intestinal tissues with in situ validation and functional macrophage assays to investigate granuloma formation. Crohn’s disease granulomas share cellular, transcriptional and spatial features with isolated lymphoid follicles, suggesting that chronic inflammation may repurpose pre-existing lymphoid structures. We identify a previously uncharacterized population of PLA2G2D-expressing macrophages enriched in isolated lymphoid follicles and at granuloma peripheries. Lymphotoxin-α1β2, LIGHT and TNF induce this macrophage programme in vitro , while TNF and low-dose lipopolysaccharide promote CXCL9 production together with PLA2G2D expression, potentially supporting effector T-cell recruitment in the granuloma environment. Conversely, SPP1-expressing macrophages preferentially occupy granuloma cores, are induced by IL-1β or hypoxia, and interact with inflammatory fibroblasts through profibrotic signalling networks. These findings define spatially and functionally distinct macrophage niches within Crohn’s disease granulomas and support a model in which inflammatory signals transform homeostatic lymphoid macrophage programmes to promote granuloma organization and fibrotic remodelling.

26 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
VGVictoria Gudiño
Victoria Gudiño
JCJae-Won Cho
Jae-Won Cho
BCBerta Caballol
Berta Caballol
ACAna M. Corraliza
Ana M. Corraliza
MVMarisol Veny
Marisol Veny
ASAZUCENA SALAS
AZUCENA SALAS
Background: Perianal fistulizing disease (PFD) is a complication that affects about 20% of Crohn’s disease (CD) patients whose etiology remains unknown. Objectives: To identify predisposing events driving fistula formation. Design: Rectal biopsies from CD patients with or without PFD (CD+PFD and CD, respectively; n=31) were collected and subjected to single-cell RNA sequencing (scRNA-seq). Functional analyses were conducted using peripheral CD3+ T cells, intestinal tissue explants, primary fibroblasts and 2D-epithelial monolayer cell cultures. Results: The rectal mucosa of CD+PFD patients is imprinted with cellular and transcriptomic alterations specific to PFD and independent of luminal inflammation, potentially driven by TL1A activation in CD4+ T cells. We identified lymphotoxin beta ( LTB or its functional heterotrimer LTα 1 β 2 ) as a novel mediator downstream of TL1A that, along with IL-22, induces a PFD-associated signature in rectal fibroblast and epithelial cells, respectively. This signature includes an increased abundance of fibroblasts, an induction of matrix-degrading enzymes, transcriptomic rewiring of the lamina propria S1 fibroblasts, and an anti-bacterial and immune responses in epithelial cells. Notably, the induction of LTα 1 β 2 and IL-22 occurs independently of TNF signaling, revealing a new TL1A-LTα 1 β 2 /IL-22 axis that remains active under anti-TNF therapy. Conclusion: Our findings revealed unique cellular alterations in the rectum of CD patients with PFD, highlighting the previously unrecognized involvement of TL1A in mediating this signature and supporting the need for exploring the role of TL1A inhibition as a therapeutic approach for PFD.